Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

John F. Langenheim PhD

John F. Langenheim PhD profile photo picture

Instructor

Institution: Medical College of Wisconsin
Department: Pathology
Division: Administration

Member of the Cancer Center


Methodologies and Techniques

  • Breast Neoplasms
  • Growth Hormone
  • Mammary Glands, Human
  • Prolactin
  • Receptors, Prolactin
  • Receptors, Somatotropin
  • Recombinant Proteins
  • Publications (15)

  • Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. (Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H) Clin Cancer Res 2018 12 15;24(24):6355-6366 PMID: 30097435 SCOPUS ID: 2-s2.0-85058487046 08/12/2018       2 Citations
  • GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers. (Liu Y, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ) Mol Endocrinol 2016 May;30(5):504-17 PMID: 27003442 PMCID: PMC4853563 SCOPUS ID: 2-s2.0-84964876556 03/24/2016       8 Citations
  • Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis. (Kim BG, Yoo JY, Kim TH, Shin JH, Langenheim JF, Ferguson SD, Fazleabas AT, Young SL, Lessey BA, Jeong JW) Hum Reprod 2015 May;30(5):1069-78 PMID: 25750101 PMCID: PMC4400199 SCOPUS ID: 2-s2.0-84929716718 03/10/2015       41 Citations
  • Dynamic analysis of GH receptor conformational changes by split luciferase complementation. (Liu Y, Berry PA, Zhang Y, Jiang J, Lobie PE, Paulmurugan R, Langenheim JF, Chen WY, Zinn KR, Frank SJ) Mol Endocrinol 2014 Nov;28(11):1807-19 PMID: 25188449 PMCID: PMC4213363 SCOPUS ID: 2-s2.0-84908349618 09/05/2014       10 Citations
  • The role of prolactin receptor in GH signaling in breast cancer cells. (Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ) Mol Endocrinol 2013 Feb;27(2):266-79 PMID: 23192981 PMCID: PMC3683809 SCOPUS ID: 2-s2.0-84873032331 11/30/2012       24 Citations
  • Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer. (Xu C, Langenheim JF, Chen WY) Breast Cancer Res Treat 2012 Jul;134(1):157-69 PMID: 22270933 SCOPUS ID: 2-s2.0-84863920205 01/25/2012       9 Citations
  • Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. (Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ) Mol Endocrinol 2011 Apr;25(4):597-610 PMID: 21310852 PMCID: PMC3063080 SCOPUS ID: 2-s2.0-79953754929 02/12/2011       39 Citations
  • Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. (Langenheim JF, Chen WY) J Endocrinol 2009 Dec;203(3):375-87 PMID: 19770179 SCOPUS ID: 2-s2.0-71949120963 09/23/2009       13 Citations
  • Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor. (Langenheim JF, Chen WY) J Recept Signal Transduct Res 2009;29(2):107-12 PMID: 19519175 SCOPUS ID: 2-s2.0-68949175303 06/13/2009       8 Citations
  • Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice. (Tomblyn S, Springs AE, Langenheim JF, Chen WY) Int J Oncol 2009 Apr;34(4):1139-46 PMID: 19287973 03/17/2009       4 Citations
  • Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. (Yang N, Langenheim JF, Wang X, Jiang J, Chen WY, Frank SJ) Mol Endocrinol 2008 Apr;22(4):978-88 PMID: 18096690 PMCID: PMC2276467 SCOPUS ID: 2-s2.0-41649098922 12/22/2007       34 Citations
  • Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. (Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY) Breast Cancer Res Treat 2008 Sep;111(2):241-50 PMID: 17955362 SCOPUS ID: 2-s2.0-40249102092 10/24/2007       28 Citations
  • Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. (Langenheim JF, Tan D, Walker AM, Chen WY) Mol Endocrinol 2006 Mar;20(3):661-74 PMID: 16269515 PMCID: PMC1402359 SCOPUS ID: 2-s2.0-33344469275 11/05/2005       23 Citations
  • The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. (Tomblyn S, Langenheim JF, Jacquemart IC, Holle E, Chen WY) Int J Oncol 2005 Nov;27(5):1381-9 PMID: 16211235 SCOPUS ID: 2-s2.0-33644653444 10/08/2005       12 Citations
  • Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A. (Langenheim JF, Chen WY) Breast Cancer Res Treat 2005 Apr;90(3):281-93 PMID: 15830142 PMCID: PMC1398053 SCOPUS ID: 2-s2.0-17744378741 04/15/2005       13 Citations
  • Last update: 03/20/2020
    jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a